Dianthus Therapeutics, Inc. · NASDAQ:DNTH
Octagon Capital Advisors LP reported a 7.10% stake in Dianthus Therapeutics, Inc. (Schedule 13G/A)
Event Dec 31, 2024 · Filed Feb 5, 2025
Octagon Capital Advisors LP reported a 7.10% stake in Dianthus Therapeutics, Inc., 2,110,167 shares, as a passive investor on Dec 31, 2024. Filed Feb 5, 2025 (Schedule 13G/A).
- Stake
- 7.10%
- Shares
- 2,110,167
- Intent
- Passive
- What changed
- Stake changed
- Filed together
- 4 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Octagon Capital Advisors LP | 7.10% | 2,110,167 |
| Octagon Investments Master Fund LP | 6.10% | 1,818,500 |
| Octagon Private Opportunities Fund II LP | 1.00% | 291,667 |
| Ting Jia | 7.10% | 2,110,167 |
Source
Related
- Dianthus Therapeutics, Inc.
- Octagon Capital Advisors LP
- Dianthus Therapeutics, Inc. shareholders
- Schedule 13G/A · Octagon Capital Advisors LP · May 14, 2026
- Schedule 13G/A · Octagon Capital Advisors LP · Nov 14, 2025
- Form 4 · Carr Edward · Sep 18, 2026
- Form 4 · Randhawa Simrat · Sep 3, 2026
- Form 4 · Read Simon · Aug 19, 2026
- Form 4 · Veness Adam M · Aug 14, 2026
- Schedule 13G/A · Sirenia Capital Management LP · Aug 14, 2026